Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald N Jones

Showing results (81-90 of 662) with videos related to

Pageof 67
Sort By:
Antimicrobial Agents and Chemotherapy|March 18, 2009
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolatesHelio S Sader, Thomas R Fritsche, Ronald N Jones
Antimicrobial Agents and Chemotherapy|December 31, 2008
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrheaThomas R Fritsche, Douglas J Biedenbach, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|October 3, 2003
Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002)Thomas R Fritsche, Helio S Sader, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|September 12, 2003
Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001)Helio S Sader, Douglas J Biedenbach, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|December 21, 2002
Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000)Ana C Gales, Helio S Sader, Ronald N Jones, et al.
The Annals of Pharmacotherapy|December 31, 2002
CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging ResistanceAlan H Mutnick, Jeffrey T Kirby, Ronald N Jones, et al.
Journal of Clinical Microbiology|June 7, 2003
Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activityTamara R Anderegg, Douglas J Biedenbach, Ronald N Jones, et al.
Journal of Clinical Microbiology|November 21, 2014
Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinoneRonald N Jones, Nicole M Holliday, Paul R Rhomberg
Diagnostic Microbiology and Infectious Disease|May 27, 2006
Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycosideHolly K Huynh, Douglas J Biedenbach, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|March 7, 2013
Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterialJames E Ross, Nicole Scangarella-Oman, Ronald N Jones
Pageof 67

Showing results (81-90 of 662) with videos related to

Sort By:
Pageof 67
Antimicrobial Agents and Chemotherapy|March 18, 2009
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolatesHelio S Sader, Thomas R Fritsche, Ronald N Jones
Antimicrobial Agents and Chemotherapy|December 31, 2008
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrheaThomas R Fritsche, Douglas J Biedenbach, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|October 3, 2003
Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002)Thomas R Fritsche, Helio S Sader, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|September 12, 2003
Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001)Helio S Sader, Douglas J Biedenbach, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|December 21, 2002
Urinary tract infection trends in Latin American hospitals: report from the SENTRY antimicrobial surveillance program (1997-2000)Ana C Gales, Helio S Sader, Ronald N Jones, et al.
The Annals of Pharmacotherapy|December 31, 2002
CANCER resistance surveillance program: initial results from hematology-oncology centers in North America. Chemotherapy Alliance for Neutropenics and the Control of Emerging ResistanceAlan H Mutnick, Jeffrey T Kirby, Ronald N Jones, et al.
Journal of Clinical Microbiology|June 7, 2003
Initial quality control evaluations for susceptibility testing of Dalbavancin (BI397), an investigational glycopeptide with potent gram-positive activityTamara R Anderegg, Douglas J Biedenbach, Ronald N Jones, et al.
Journal of Clinical Microbiology|November 21, 2014
Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinoneRonald N Jones, Nicole M Holliday, Paul R Rhomberg
Diagnostic Microbiology and Infectious Disease|May 27, 2006
Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycosideHolly K Huynh, Douglas J Biedenbach, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|March 7, 2013
Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterialJames E Ross, Nicole Scangarella-Oman, Ronald N Jones
Pageof 67